CN101143148B - 重楼皂甙ⅰ及其衍生物的应用 - Google Patents
重楼皂甙ⅰ及其衍生物的应用 Download PDFInfo
- Publication number
- CN101143148B CN101143148B CN2007101561323A CN200710156132A CN101143148B CN 101143148 B CN101143148 B CN 101143148B CN 2007101561323 A CN2007101561323 A CN 2007101561323A CN 200710156132 A CN200710156132 A CN 200710156132A CN 101143148 B CN101143148 B CN 101143148B
- Authority
- CN
- China
- Prior art keywords
- saponin
- pariphyllin
- cell
- paris
- drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- IUCHKMAZAWJNBJ-RCYXVVTDSA-N oleanolic acid 3-O-beta-D-glucosiduronic acid Chemical compound O([C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2C1(C)C)C)(C)CC[C@]1(CCC(C[C@H]14)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O IUCHKMAZAWJNBJ-RCYXVVTDSA-N 0.000 title description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims abstract description 33
- 239000003814 drug Substances 0.000 claims abstract description 31
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 22
- 238000002360 preparation method Methods 0.000 claims abstract description 13
- 229940079593 drug Drugs 0.000 claims abstract description 10
- 201000005202 lung cancer Diseases 0.000 claims abstract description 7
- 208000020816 lung neoplasm Diseases 0.000 claims abstract description 7
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 3
- LWNOIQJAJMHMSM-UHFFFAOYSA-N Pariphyllin Natural products O1C2(OCC(C)CC2)C(C)C(C2(CCC3C4(C)CC5)C)C1CC2C3CC=C4CC5OC(C(C1OC2C(C(O)C(CO)O2)O)O)OC(CO)C1OC1OC(C)C(O)C(O)C1O LWNOIQJAJMHMSM-UHFFFAOYSA-N 0.000 claims description 49
- 238000011282 treatment Methods 0.000 claims description 8
- 210000004881 tumor cell Anatomy 0.000 claims description 5
- LRRDDWMXYOSKIC-UHFFFAOYSA-N (25R)-diosgenin-3-O-alpha-L-arabinofuranosyl(1-4)-[alpha-L-rhamnopyranosyl(1-2)]-beta-D-glucopyranoside Natural products O1C2(OCC(C)CC2)C(C)C(C2(CCC3C4(C)CC5)C)C1CC2C3CC=C4CC5OC(C(C1O)OC2C(C(O)C(O)C(C)O2)O)OC(CO)C1OC1OC(CO)C(O)C1O LRRDDWMXYOSKIC-UHFFFAOYSA-N 0.000 claims description 2
- HSOMTBUZSIVDQK-UHFFFAOYSA-N Lililancifoloside A Natural products O1C2(OCC(C)CC2)C(C)C(C2(CCC3C4(C)CC5)C)C1CC2C3CC=C4CC5OC(C(C1O)OC2C(C(O)C(O)C(C)O2)O)OC(CO)C1OC1OCC(O)C(O)C1O HSOMTBUZSIVDQK-UHFFFAOYSA-N 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 229940124531 pharmaceutical excipient Drugs 0.000 claims description 2
- 230000004663 cell proliferation Effects 0.000 claims 1
- 210000004027 cell Anatomy 0.000 abstract description 37
- 208000032839 leukemia Diseases 0.000 abstract description 23
- 238000002474 experimental method Methods 0.000 abstract description 14
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 abstract description 13
- 230000000694 effects Effects 0.000 abstract description 13
- 238000004113 cell culture Methods 0.000 abstract description 10
- 239000001397 quillaja saponaria molina bark Substances 0.000 abstract description 10
- 229930182490 saponin Natural products 0.000 abstract description 10
- 150000007949 saponins Chemical class 0.000 abstract description 10
- 229960004316 cisplatin Drugs 0.000 abstract description 9
- 201000011510 cancer Diseases 0.000 abstract description 7
- 239000002246 antineoplastic agent Substances 0.000 abstract description 4
- 230000012010 growth Effects 0.000 abstract description 4
- 210000003958 hematopoietic stem cell Anatomy 0.000 abstract description 4
- 241001465754 Metazoa Species 0.000 abstract description 3
- 238000000338 in vitro Methods 0.000 abstract description 3
- 230000001093 anti-cancer Effects 0.000 abstract description 2
- 239000000126 substance Substances 0.000 abstract description 2
- 229940044683 chemotherapy drug Drugs 0.000 abstract 2
- 231100000331 toxic Toxicity 0.000 abstract 2
- 230000002588 toxic effect Effects 0.000 abstract 2
- 235000005903 Dioscorea Nutrition 0.000 abstract 1
- 241000234273 Dioscorea Species 0.000 abstract 1
- 235000000504 Dioscorea villosa Nutrition 0.000 abstract 1
- 241000219100 Rhamnaceae Species 0.000 abstract 1
- 230000000118 anti-neoplastic effect Effects 0.000 abstract 1
- 235000004879 dioscorea Nutrition 0.000 abstract 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 20
- 241000282414 Homo sapiens Species 0.000 description 14
- 229910002092 carbon dioxide Inorganic materials 0.000 description 10
- 241001597008 Nomeidae Species 0.000 description 9
- 201000005296 lung carcinoma Diseases 0.000 description 7
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 238000011580 nude mouse model Methods 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 5
- 239000001569 carbon dioxide Substances 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 230000004614 tumor growth Effects 0.000 description 5
- 210000000683 abdominal cavity Anatomy 0.000 description 4
- 230000000259 anti-tumor effect Effects 0.000 description 4
- 230000006907 apoptotic process Effects 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000002512 chemotherapy Methods 0.000 description 4
- 238000011254 conventional chemotherapy Methods 0.000 description 4
- 230000003203 everyday effect Effects 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000008363 phosphate buffer Substances 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 230000001629 suppression Effects 0.000 description 4
- 241000699660 Mus musculus Species 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 239000012531 culture fluid Substances 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000006196 drop Substances 0.000 description 3
- 239000000178 monomer Substances 0.000 description 3
- 210000005259 peripheral blood Anatomy 0.000 description 3
- 239000011886 peripheral blood Substances 0.000 description 3
- 238000002689 xenotransplantation Methods 0.000 description 3
- HDXIQHTUNGFJIC-UHFFFAOYSA-N (25R)-spirost-5-en-3beta-ol 3-O-<O-alpha-L-rhamnopyranosyl-(1-->2)-beta-D-glucopyranoside> Natural products O1C2(OCC(C)CC2)C(C)C(C2(CCC3C4(C)CC5)C)C1CC2C3CC=C4CC5OC1OC(CO)C(O)C(O)C1OC1OC(C)C(O)C(O)C1O HDXIQHTUNGFJIC-UHFFFAOYSA-N 0.000 description 2
- -1 4-O-arabinofuranosyl-2-O-rhamnopyranosyl-β-D-glucopyranosyl dioscin Chemical compound 0.000 description 2
- VNONINPVFQTJOC-RXEYMUOJSA-N Collettiside III Natural products O([C@@H]1[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O2)[C@H](CO)O[C@@H]1O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]5[C@H](C)[C@@]6(O[C@H]5C4)OC[C@H](C)CC6)CC3)CC=2)CC1)[C@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O1 VNONINPVFQTJOC-RXEYMUOJSA-N 0.000 description 2
- 101001074035 Homo sapiens Zinc finger protein GLI2 Proteins 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 102100035558 Zinc finger protein GLI2 Human genes 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- 229940120638 avastin Drugs 0.000 description 2
- 239000012930 cell culture fluid Substances 0.000 description 2
- CJNUQCDDINHHHD-APRUHSSNSA-N dioscin Natural products C[C@@H]1CC[C@@]2(OC1)O[C@H]3C[C@H]4[C@@H]5CC=C6C[C@H](CC[C@@H]6[C@H]5CC[C@]4(C)[C@H]3[C@@H]2C)O[C@@H]7O[C@H](CO)[C@@H](O[C@@H]8O[C@@H](C)[C@H](O)[C@@H](O)[C@H]8O)[C@H](O)[C@H]7O[C@@H]9O[C@@H](C)[C@H](O)[C@@H](O)[C@H]9O CJNUQCDDINHHHD-APRUHSSNSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 210000003677 hemocyte Anatomy 0.000 description 2
- 229940000351 hemocyte Drugs 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 2
- 239000002574 poison Substances 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- VNONINPVFQTJOC-UHFFFAOYSA-N polyphyllin III Natural products O1C2(OCC(C)CC2)C(C)C(C2(CCC3C4(C)CC5)C)C1CC2C3CC=C4CC5OC(C(C1O)OC2C(C(O)C(O)C(C)O2)O)OC(CO)C1OC1OC(C)C(O)C(O)C1O VNONINPVFQTJOC-UHFFFAOYSA-N 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 150000005856 steroid saponins Chemical class 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- GOLCXWYRSKYTSP-UHFFFAOYSA-N Arsenious Acid Chemical compound O1[As]2O[As]1O2 GOLCXWYRSKYTSP-UHFFFAOYSA-N 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- 206010011793 Cystitis haemorrhagic Diseases 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 206010045170 Tumour lysis syndrome Diseases 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 238000010322 bone marrow transplantation Methods 0.000 description 1
- 208000003362 bronchogenic carcinoma Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 239000012997 ficoll-paque Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 238000011134 hematopoietic stem cell transplantation Methods 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 201000002802 hemorrhagic cystitis Diseases 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- HYFHYPWGAURHIV-UHFFFAOYSA-N homoharringtonine Natural products C1=C2CCN3CCCC43C=C(OC)C(OC(=O)C(O)(CCCC(C)(C)O)CC(=O)OC)C4C2=CC2=C1OCO2 HYFHYPWGAURHIV-UHFFFAOYSA-N 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 229960003685 imatinib mesylate Drugs 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000000088 lip Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000001167 myeloblast Anatomy 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- HYFHYPWGAURHIV-JFIAXGOJSA-N omacetaxine mepesuccinate Chemical compound C1=C2CCN3CCC[C@]43C=C(OC)[C@@H](OC(=O)[C@@](O)(CCCC(C)(C)O)CC(=O)OC)[C@H]4C2=CC2=C1OCO2 HYFHYPWGAURHIV-JFIAXGOJSA-N 0.000 description 1
- 229960002230 omacetaxine mepesuccinate Drugs 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 210000004976 peripheral blood cell Anatomy 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 208000010380 tumor lysis syndrome Diseases 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2007101561323A CN101143148B (zh) | 2007-10-16 | 2007-10-16 | 重楼皂甙ⅰ及其衍生物的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2007101561323A CN101143148B (zh) | 2007-10-16 | 2007-10-16 | 重楼皂甙ⅰ及其衍生物的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101143148A CN101143148A (zh) | 2008-03-19 |
CN101143148B true CN101143148B (zh) | 2010-12-08 |
Family
ID=39206004
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2007101561323A Active CN101143148B (zh) | 2007-10-16 | 2007-10-16 | 重楼皂甙ⅰ及其衍生物的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101143148B (zh) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102920892B (zh) * | 2012-05-29 | 2015-02-18 | 李宗清 | 治疗肺癌的中药制剂及其制备方法 |
CN104334571B (zh) * | 2012-06-13 | 2016-08-31 | 杭州本生药业有限公司 | 重楼皂苷i的酰化衍生物、及其制备方法和应用 |
WO2013185613A1 (zh) * | 2012-06-13 | 2013-12-19 | 杭州本生药业有限公司 | 重楼皂苷i的酰化衍生物、及其制备方法和应用 |
CN104887690B (zh) * | 2014-03-07 | 2018-04-13 | 复旦大学 | 重楼皂苷在制备抗肿瘤药物中的应用 |
CN105796580A (zh) * | 2014-12-31 | 2016-07-27 | 上海中医药大学附属龙华医院 | 一种蛋白酶体活性抑制剂pi在制备防治骨肉瘤药物或保健食品中的应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1707238A1 (en) * | 2003-12-19 | 2006-10-04 | Ming Qi Oncology Chinese Medicines, Inc. | Pharmaceuticals of chinese traditional medicine of treating lung cancer and preparation method thereof |
CN1850095A (zh) * | 2006-02-22 | 2006-10-25 | 天津大学 | 重楼皂苷化合物的应用 |
CN1899491A (zh) * | 2006-06-30 | 2007-01-24 | 浙江大学 | 一种重楼总皂苷的制备方法及其用途 |
-
2007
- 2007-10-16 CN CN2007101561323A patent/CN101143148B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1707238A1 (en) * | 2003-12-19 | 2006-10-04 | Ming Qi Oncology Chinese Medicines, Inc. | Pharmaceuticals of chinese traditional medicine of treating lung cancer and preparation method thereof |
CN1850095A (zh) * | 2006-02-22 | 2006-10-25 | 天津大学 | 重楼皂苷化合物的应用 |
CN1899491A (zh) * | 2006-06-30 | 2007-01-24 | 浙江大学 | 一种重楼总皂苷的制备方法及其用途 |
Non-Patent Citations (7)
Title |
---|
cui yan etal.A diosgenyl saponin extracted from Rhizomesofparispolyphylla smith:structure elucidated from NMR data.波谱学杂志23 3.2006,23(3),367-372. |
cui yan etal.A diosgenyl saponin extracted from Rhizomesofparispolyphylla smith:structure elucidated from NMR data.波谱学杂志23 3.2006,23(3),367-372. * |
James C.N etal.structure characterization ofhaemostaticdiosgeninglycosidesfrom paris polyphlia.phytochemistry7 24.1985,7(24),1561-1565. |
James C.N etal.structure characterization ofhaemostaticdiosgeninglycosidesfrom paris polyphlia.phytochemistry7 24.1985,7(24),1561-1565. * |
JP昭60-1130A 1985.01.07 |
唐炳兰.中药重楼的研究进展.右江明祖医学院学报 6.2006,(6),1062-1064. |
唐炳兰.中药重楼的研究进展.右江明祖医学院学报 6.2006,(6),1062-1064. * |
Also Published As
Publication number | Publication date |
---|---|
CN101143148A (zh) | 2008-03-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8858953B2 (en) | Herbal composition for treating cancer | |
CN101143148B (zh) | 重楼皂甙ⅰ及其衍生物的应用 | |
CN102008650B (zh) | 一种治疗肿瘤的复方中药制剂及其制备方法 | |
CN101502579B (zh) | 一种用于治疗消化系肿瘤的中药组合物及其制备方法 | |
CN104434939B (zh) | 三七皂苷r7和冬凌草甲素减毒增效抗肿瘤药物组合物及其应用 | |
CN101229175A (zh) | 一对原人参二醇衍生物和它们混合体的医药用途 | |
CN108186794B (zh) | 一种治疗肺癌的中药组合物及其制备方法和应用 | |
CN104189782A (zh) | 一种抗肿瘤的药物组合物 | |
CN1939311B (zh) | 一种新的人参皂苷苷元衍生物制剂及其用途 | |
CN101953839B (zh) | 一种具有抗急性髓性白血病作用的复方药物组合物 | |
CN109481454A (zh) | 抗肿瘤组合物及其在制备抗肿瘤或抑制癌细胞药物方面的应用、抗肿瘤药物 | |
CN102225089B (zh) | 治疗癌症的药物组合物、药物制剂及应用和制法 | |
CN100406026C (zh) | 一种治疗慢性胃炎、胃癌的药物及其制备方法 | |
CN109106716A (zh) | 芒柄花素与氟尿嘧啶的组合在制备抗肿瘤药物中的用途 | |
CN101199534B (zh) | 一种原人参二醇衍生物的抗肿瘤用途 | |
Zhijun et al. | The effect-enhancing and toxicity-reducing action of the extract of herba Scutellariae barbatae for chemotherapy in hepatoma H22 tumor-bearing mice | |
CN102440994A (zh) | 灵芝酸g在肿瘤治疗中作为免疫增效剂和超抗原依赖的治疗药物的应用 | |
CN114028381B (zh) | 一种用于治疗卵巢癌的药物及其应用 | |
CN103191268B (zh) | 一种治疗肺癌的中药组合物 | |
CN102139037A (zh) | 重楼总皂苷在制备抗癌药辅助药物的应用 | |
CN110123825B (zh) | 一种包含去甲氧柔红霉素的药物组合物 | |
CN102309493B (zh) | 一种抗癌药物组合物 | |
Chang et al. | Experimental study on growth inhibition against anaplastic thyroid carcinoma of animal model by application of ginsenoside Rg1 | |
CN105769888A (zh) | 竹节人参皂苷IVa在制备抗肿瘤药物中的应用 | |
CN111632066A (zh) | 治疗和/或预防卵巢癌的药物组合物及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: HANGZHOU BENSHENG PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: ZHEJIANG UNIVERSITY Effective date: 20110210 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 310027 NO.38, ZHEDA ROAD, XIHU DISTRICT, HANGZHOU CITY, ZHEJIANG PROVINCE TO: 310051 4/F, BUILDING 6, NO.88, JIANGLING ROAD, BINJIANG DISTRICT, HANGZHOU CITY, ZHEJIANG PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20110210 Address after: 4 Building 6, building 88, 310051 Jiangling Road, Binjiang District, Zhejiang, Hangzhou Patentee after: HANGZHOU BENSHENG PHARMACEUTICAL Co.,Ltd. Address before: 310027 Hangzhou, Zhejiang Province, Xihu District, Zhejiang Road, No. 38, No. Patentee before: Zhejiang University |
|
DD01 | Delivery of document by public notice |
Addressee: HANGZHOU BENSHENG PHARMACEUTICAL Co.,Ltd. Document name: Notification to Pay the Fees |
|
DD01 | Delivery of document by public notice | ||
DD01 | Delivery of document by public notice |
Addressee: Lai Hongxi Document name: payment instructions |
|
DD01 | Delivery of document by public notice |